| NCT ID | NCT07456449 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University of Vienna |
| Condition | Longevity |
| Study Type | INTERVENTIONAL |
| Enrollment | 125 participants |
| Start Date | 2026-04-22 |
| Primary Completion | 2028-02 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 125 participants in total. It began in 2026-04-22 with a primary completion date of 2028-02.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The goal of this clinical trial is to learn if daily collagen peptide supplementation can stabilize or lengthen telomeres and improve related markers of cellular aging in adults aged 50-70 years with overweight and low-to-moderate physical activity (healthy volunteers without major chronic disease). Main questions it aims to answer are: Does six months of collagen peptides stabilize or extend telomere length and increase telomerase activity compared with placebo? Are any telomere-related changes associated with lower inflammation, healthier body composition, and better functional health? Researchers will compare collagen as an intervention to a placebo group to see if collagen will influence aging markers. Participants will take collagen peptides or a placebo daily for 24 weeks. They will attend three study visits: one before starting the intervention (T0), one at 3 months (T1), and one at 6 months (T2). At each visit, blood samples will be collected to measure telomere length, telomerase activity, and inflammation/redox markers. Participants will also undergo body composition assessments using bioelectrical impedance, complete functional tests of muscle strength and mobility, and fill out questionnaires on health and vitality.
Eligibility Criteria
Inclusion Criteria: * Adults aged 50-70 years; both male and female participants are eligible * Body mass index (BMI) 25-30 kg/m² * Low to moderate physical activity: not meeting current WHO recommendations (\<150 minutes/week) or ≤2 sessions/week structured training * Able to live independently and mobile in daily life * No regular resistance training within the past 6 months * Provision of written informed consent Exclusion Criteria: * Diagnosed chronic diseases relevant to the immune system, metabolism, or cellular aging (e.g., diabetes mellitus, cancer, cardiovascular, rheumatologic diseases) * Use of immunomodulatory, systemic anti-inflammatory, or hormonal medications (e.g., corticosteroids, immunosuppressants) * Acute infections or surgeries within the last 3 months * Regular use of supplements known to affect oxidative stress or cellular aging (e.g., high-dose antioxidants, CoQ10, omega-3 fatty acids, high-dose vitamin D) * Participation in another clinical study within the last 3 months * Vegetarian or vegan diet (product contains animal-derived collagen)
Contact & Investigator
Frequently Asked Questions
Who can join the NCT07456449 clinical trial?
This trial is open to participants of all sexes, aged 50 Years or older, up to 70 Years, studying Longevity. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07456449 currently recruiting?
Yes, NCT07456449 is actively recruiting participants. Contact the research team at daniel.koenig@univie.ac.at for enrollment information.
Where is the NCT07456449 trial being conducted?
This trial is being conducted at Vienna, Austria.
Who is sponsoring the NCT07456449 clinical trial?
NCT07456449 is sponsored by University of Vienna. The trial plans to enroll 125 participants.